GDC-0425

DB14791InvestigationalSmall molecule

GDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or...

Mechanism: Pharmacologically active on Serine/threonine-protein kinase Chk1
Curator reviewed
Formula / weight: C₁₈H₁₉N₅O · 321.384 g/mol (avg)
Code names: GDC-0425 · RG-7602

Resolves to

Compound

UNII4N173XZ7SXCAS1627539-18-7ChEMBLCHEMBL5314388ChEBI759103PubChem58266779

Structure

InChIKeyXEZLBMHDUXSICI-UHFFFAOYSA-NSMILESCCN1CCC(CC1)OC1=C(N=CC2=C1C1=C(N2)N=CC=C1)C#N

Targets

O14757CHEK1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with GDC-0425, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account